ArticleBMC public health2026
Trends in cause of death among patients with non-small cell lung cancer in the United States from 2000 to 2021: a SEER-based study.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe diagnosis and treatment of non-small cell lung cancer (NSCLC) has made rapid progress. Cancer survivors with prolonged survival time are also susceptible to non-cancer diseases. The study aims to identify the causes of death in NSCLC for improved management and survival.
methodsData were extracted from National Cancer Institute’s Surveillance, Epidemiology, and End Results program (2000–2021). Cumulative incidence of mortality in NSCLC patients, considering both lung cancer-related and other causes, were calculated using the competing-risks regression model. The trend in annual age-standardized mortality rate from various causes of death in NSCLC was described by the joinpoint regression model. The distributions of the leading 10 non-cancer causes of death in NSCLC were reported via stacked area charts and bar charts. Moreover, subgroup analyses based on tumor stage, age, and pathological type were conducted.
resultsAmong all 768,309 patients with NSCLC, mortality from lung cancer accounted for approximately 76.4% deaths (479,520/627,976). However, the proportion of deaths attributable to lung cancer gradually decreased over time, although it remained the predominant cause of death. The cumulative incidence of mortality from lung cancer ranged from 52% to 69% from 24 to 144 months after diagnosis, while that of mortality from other causes ranged from 12% to 27%. Moreover, there was a larger-magnitude decrease in the annual mortality from lung cancer than other causes (average annual percent change [AAPC] − 4.38% (− 5.65 to − 3.00%) vs. − 2.43% (− 3.69 to − 0.93%)), and the proportion of deaths from other causes increased from 16.18% to 35.34%. The change was particularly evident among the elderly (AAPC-lung cancer: −5.21% (− 5.72 to − 4.75%); AAPC-other causes: 0.60% (0.14 to 1.01%)) and those in stage I and in situ (AAPC-lung cancer: −8.42% (− 10.14 to − 6.54%); AAPC-other causes: 3.93% (0.60 to 10.57%)). Diseases of heart, chronic obstructive pulmonary disease and various infections were relatively more prevalent in non-cancer deaths.
conclusionNSCLC is a complex disease with multiple factors involved, and the therapeutic alternatives have significantly increased. While lung cancer-related death remains the primary cause, the proportion of non-lung cancer-related death has increased, which requires attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.